Driven by a desire to help ex-servicemembers with mental illness, GOP lawmakers led a failed campaign last year to persuade the Biden administration to approve psychedelic drugs. Now they may have found the ally they need in President Donald Trump’s health secretary, Robert F. Kennedy Jr. RFK Jr. is bringing psychedelics to the Republican party
CTIS 2025: Automated Assessment Auditing Across MindMed’s Pivotal Programs Presentedy by: Dan Karlin, Chief Medical Officer, MindMed
MAPS supporting MM-120 Trial - Poston Instagram. I would say this is big. https://www.instagram.com/p/DL-eltENqfw/?igsh=bzJscXQ4NzVyMzl1
RFK Jr. and other Trump officials embrace psychedelics after FDA setback https://apnews.com/article/psychede...bogaine-mdma-4e59a3eb2d23d98f2579d25c73c34e9b
$MNMD J&J doesn't have to 'do deals out of desperation' despite facing patent cliffs: CFO https://finance.yahoo.com/news/jj-d...spite-facing-patent-cliffs-cfo-112624430.html "Our portfolio and pipeline position us for elevated growth in the second half of the year, with game-changing approvals and submissions anticipated in areas like lung and bladder cancer, major depressive disorder, psoriasis, surgery, and cardiovascular, which will extend and improve lives in transformative ways," MM-120 for MDD Jay Woods, Freedom Capital Markets' chief global strategist, recently told Yahoo Finance "all eyes are on how J&J and others are going to manage their M&A strategy to account for the significant revenue losses attributed to patent expiries. Wolk told Yahoo Finance the company is looking at a strong balance sheet, with $20 billion on hand, plus capital deployment of $55 billion in the last few years for large to small M&A deals. Of the $55 billion, $10 billion was used on 80 small deals, he said.
List of Patent Activity on 2025 for MindMed US20250205196 – Formulations of Psilocin with Enhanced Stability Jurisdiction: United States Publication Date: June 26, 2025 Patent Link - https://patentscope.wipo.int/search/en/detail.jsf?docId=US458475369&_cid=P22-MD7DGB-14617-2 Summary: Covers novel psilocin formulations with improved chemical stability. Strategic Value: Strengthens MindMed’s ability to commercialize shelf-stable, fast-acting psychedelic therapies in the U.S. EP4551680 – Methods of Manufacture of R-MDMA Jurisdiction: European Patent Office Publication Date: May 14, 2025 Patent Link - https://patentscope.wipo.int/search/en/detail.jsf?docId=EP455657588&_cid=P22-MD7DGB-14617-9 Summary: Describes synthetic methods specifically for the R-enantiomer of MDMA. Strategic Value: Expands MindMed’s IP footprint in Europe and enables proprietary production of next-generation empathogenic compounds. WO2025128594 – Methods of Treating Generalized Anxiety Disorder Jurisdiction: International (WIPO/PCT) Publication Date: June 19, 2025 Patent Link - https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2025128594&_cid=P22-MD7DGB-14617-12 Summary: Claims the use of psychoactive compounds for the treatment of Generalized Anxiety Disorder. Strategic Value: Broadens MindMed’s therapeutic claims globally and supports expansion into anxiety-related indications. US20250019359 – R-MDMA Crystal Forms Jurisdiction: United States Publication Date: January 16, 2025 Patent Link - https://patentscope.wipo.int/search/en/detail.jsf?docId=US446172274&_cid=P22-MD7DGB-14617-3 Summary: Discloses crystalline polymorphs of R-MDMA, which influence drug stability and bioavailability. Strategic Value: Secures commercial control over specific drug forms as MindMed moves toward clinical and market-ready formulations in the U.S. AU2025204612 – MDMA Enantiomers Jurisdiction: Australia Publication Date: July 3, 2025 Patent Link - https://patentscope.wipo.int/search/en/detail.jsf?docId=AU458866182&_cid=P22-MD7DGB-14617-7 Summary: Covers both R- and S-enantiomers of MDMA, including their compositions and uses. Strategic Value: Enhances MindMed’s global IP portfolio and supports international protection of its novel empathogen drug candidates.
PBS - RFK Jr. suggests psychedelic therapy for depression and trauma has Trump administration’s support https://www.pbs.org/newshour/health...for-psychedelic-therapy-for-depression-trauma
Mind Medicine: Heading In The Right Direction https://seekingalpha.com/article/4803842-mind-medicine-heading-in-the-right-direction
AbbVie in Talks to Acquire Gilgamesh in $1 Billion Deal https://www.bloomberg.com/news/arti...embedded-checkout=true&leadSource=reddit_wall AbbVie Inc. is in talks to acquire mental health therapeutics company Gilgamesh Pharmaceuticals in a deal highlighting growing takeover interest in the sector, according to people familiar with the matter.A potential deal could value privately held Gilgamesh at about $1 billion, the people said, asking not to be identified because the information is private. An announcement could be made in the coming weeks, the people said.Deliberations are ongoing and could still be delayed or fall apart, according to the people. A representative for AbbVie, which is scheduled to report earnings on Thursday, declined to comment, while Gilgamesh couldn’t be reached for comment.An acquisition would come a little more than a year after AbbVie and Gilgamesh entered into an option-to-license agreement to develop novel therapies for psychiatric disorders.Gilgamesh is developing what are known as neuroplastogens, a type of next-generation psychedelic compound. A deal would bolster AbbVie’s pipeline of potential treatments for psychiatric disorders after a drug it acquired for schizophrenia failed in mid-stage trials last year.AbbVie sells another drug, Vraylar, for schizophrenia and bipolar disorder.Separately, Atai Life Sciences NV is working with an investment bank to field early stage interest from major industry players, the people said. The Peter Thiel-backed firm, which recently acquired Beckley Psytech, has received positive results from a recent mid-stage trial of a psychedelic nasal spray dubbed BPL-003. A representative for Atai declined to comment.Psychedelic drugs for treating depression could be nearing a breakthrough over the next two years, with major late stage trials coming set to deliver key readouts, according to Bloomberg Intelligence analyst Jean Rivera Irizarry.Led by founder and Chief Executive Officer Jonathan Sporn, Gilgamesh focuses on developing treatments for depression, anxiety, drug addiction and other mental illnesses. In May, the company announced positive top-line results in a mid-stage trial for GM-2505, which targets major depressive disorders.“MindMed, Cybin and Gilgamesh are leading efforts in a fast-moving field aimed at large, underserved populations, with consensus projecting about $4.5 billion in sales for the segment by 2032,” he said in a note in April.
MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025 NEW YORK--(BUSINESS WIRE)-- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a live webcast at 4:30 p.m. EDT on Thursday, July 31, 2025 to report financial results for the first quarter ended June 30, 2025, and discuss recent business updates. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, ir.mindmed.co, and archived for at least 30 days after the webcast. Those who plan on participating are advised to join 15 minutes prior to the start time. https://edge.media-server.com/mmc/p/mjk4bs7w
